Clinical Trial Update: Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses immunogenicity and safety of a fractional intradermal booster dose of the inactivated poliovirus vaccine (IPV) compared with the ful…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• IPV (inactivated poliovirus vaccine) (inactivated poliovirus vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Poliomyelitis | Phase 2 | Status: COMPLETED